AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Elan Corp plc: Elan and Biogen Idec announce initiation of Antegren rheumatoid arthritis trial.
(From Chemical Business NewsBase - Press Release)
Elan Corp plc and Biogen Idec announced that an Investigational New Drug Application for Antegren (natalizumab) for the treatment of rheumatoid arthritis has been filed with the US Food and Drug Administration. The commencement of a Phase II clinical trial is on track to begin in 1H 2004. Natalizumab is of interest in moderate-to-severe rheumatoid arthritis because of its novel mechanism of action. The rheumatoid arthritis study will be a Phase II, multi-centre, double-blind, placebo-controlled study of the efficacy, safety and tolerability of intravenous natalizumab (300 mg) in patients with moderate-to-severe …
-
- Biogen Idec researchers identify potential new pathway in rheumatoid...
-
News wire article from: Chemical Business Newsbase
August 15, 2006
700+ words
-
- Roche and Biogen Idec discontinue clinical development of ocrelizumab for...
-
News wire article from: Chemical Business Newsbase
June 30, 2010
700+ words
-
- Genentech and Biogen Idec announce positive results from first Phase III...
-
News wire article from: Chemical Business Newsbase
December 11, 2009
700+ words
-
- Biogen Idec announces top-line results from Phase II clinical trial of...
-
News wire article from: Chemical Business Newsbase
October 9, 2008
700+ words
-
- Elan and Biogen Idec announce Tysabri safety evaluation findings in Crohn's...
-
News wire article from: Asia Africa Intelligence Wire
October 17, 2005
700+ words
